Thyroglobulin

Summary

Thyroglobulin (CHEMBL1201650) is an approved unknown; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201650
Name	Thyroglobulin
Type	Unknown
Max phase	4

Also known as: Proloid, Thyroglobulin, Thyroglobuline, Tiroglobulina, THYROGLOBULIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07056218	Not specified	NOT_YET_RECRUITING	Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).